Investing.com -- AbbVie (NYSE:ABBV) has lifted his full-year income forecast, as the pharmaceutical group said its was seeing "momentum" in its operations after third-quarter net revenue topped ...

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and ...

The CEO of Hungarian pharmaceutical company Richter ... data that could decide whether the equity rally can sustain itself. AbbVie shares fell over 12% on Monday after an experimental ...

Michael, chief executive officer, AbbVie. "Our new Cerevel colleagues share our commitment to deliver meaningful change for patients living with neurological and psychiatric conditions.

Michael, chief executive officer, AbbVie. Skyrizi and Rinvoq revenues were up 50.8% Y/Y to $3.2B and 45.3% to $1.6B, respectively, during the quarter, as the immunology portfolio generated over $ ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

As a leading provider of direct-to-patient and direct-to-physician marketing solutions, Health Monitor Network is once again expanding its senior leadership team during this period of strong growth.

Investing.com -- AbbVie (NYSE:ABBV) has lifted his full-year income forecast, as the pharmaceutical group said its was seeing "momentum" in its operations after third-quarter net revenue topped ...

Skyrizi holds biologic share leadership in approximately 30 countries and boasts a “best-in-class profile” that presents a “very high bar” for rivals, AbbVie's chief commercial officer ...

Richard Gonzalez listed T-cell engagers as a modality in which AbbVie had a high level of interest before he stepped down as CEO of the company. Responding to an analyst question about AbbVie’s ...

AbbVie Inc. raised its full-year profit forecast as demand for its top-selling anti-inflammatory drugs, Rinvoq and Skyrizi, ...